Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation
Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital
Study, Europe, November 2023 to May 2024
Egészségbiztonság Nemzeti Laboratórium(RRF-2.3.1-21-2022-00006) Támogató: NKFIH
Szakterületek:
Vakcinák
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines
against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant
period using a multicentre test-negative case-control study in Europe. We included
older adults (>= 65 years) hospitalised with severe acute respiratory infection from
November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at
60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection
against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.